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Background: T cell immunoglobulin mucin containing mole-
cule (TIM)-3 is expressed in differentiated Th1 cells and is in-
volved in the suppression of the cytokine production by these 
cells. However, the regulation of the expression of other T 
cell genes by TIM-3 is unclear. Herein, we attempted to iden-
tify differentially expressed genes in cells abundantly ex-
pressing TIM-3 compared to cells with low expression of 
TIM-3. Methods: TIM-3 overexpressing cell clones were es-
tablished by transfection of Jurkat T cells with TIM-3 ex-
pression vector. For screening of differentially expressed 
genes, gene fishing technology based on reverse tran-
scription-polymerase chain reaction (RT-PCR) using an an-
nealing control primer system was used. The selected candi-
date genes were validated by semi quantitative and real-time 
RT-PCR. Results: The transcription of TIMP-1, IFITM1, PAR3 
and CCL1 was different between TIM-3 overexpressing cells 
and control cells. However, only CCL1 transcription was sig-
nificantly different in cells transiently transfected with TIM3 
expression vector compared with control cells. CCL1 tran-
scription was increased in primary human CD4
＋ T cells 
abundantly expressing TIM-3 but not in cells with low ex-
pression of TIM-3. Conclusion: CCL1 was identified as a dif-
ferentially transcribed gene in TIM-3-expressing CD4
＋ T 
cells.
[Immune Network 2011;11(4):203-209]
INTRODUCTION
TIM-3 is a transmembrane protein containing immunoglobulin 
V  like domain, mucin domain, transmembrane domain and 
cytoplasmic domain. TIM-3 plays important roles in immune 
responses and the pathogenesis of several diseases (1). With 
its blocking antibody or its soluble fusion protein TIM-3-Ig, 
Th1 immune response as well as anti-tumor immunity is en-
hanced (2-4). Also, induction of tolerance in an experimental 
transplantation model is abrogated by injection of TIM-3 anti-
body  (5).  Furthermore,  dysregulation  of  T  cell  TIM-3  ex-
pression is observed in several autoimmune diseases includ-
ing  multiple  sclerosis,  rheumatoid  arthritis  and  Crohn’s  dis-
ease  (6-8).
    Galectin-9 and phosphatidylserine have been identified as 
TIM-3 ligands. Galectin-9 was originally identified as a potent 
eosinophil  chemoattractant  produced  and  released  by  anti-
gen-stimulated T cells (9). Galectin-9 induces intracellular cal-
cium flux, aggregation and death of in vitro cultured Th1 cells 
in a manner that is dependent on Tim-3, and administration 
of  galectin-9  in  vivo  results  in  selective  loss  of  interfer-
on-gamma-producing  cells  and  suppression  of  Th1  auto-
immunity (10). In the other hand, phosphatidylserine, which 
is normally localized to the inner leaflet of the plasma mem-
brane, is exposed on the cell surface when the cell is acti-
vated or undergoes apoptosis. TIM-3 on monocytes and den-
dritic  cells  binds  phosphatidylserine  on  apoptotic  cells  and 
enhances presentation of antigen expressed in the apoptotic 
cells  through  the  upregulation  of  endocytosis  (11).
    In this study, we wanted to identify the genes that were 
differentially expressed in T cells by TIM3 expression. Using 
TIM3 overexpressing Jurkat T cell lines and panels of degen-
erate primer sets we found three genes (TIMP-1, IFITM1 and 
CCL1) that were up-regulated in TIM3 overexpressing cells, 
and one gene (PAR3) that was down-regulated in TIM3 over-TIM-3 Increases CCL1 Transcription
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Table I. Primers used for semiquantitive RT-PCR
Product 
Clone 
Sequence length
name
(bp)
D6 CAAGTTCAAGTATTCTTTATTCAAAGTTG 819
CTGCAAAGCACAGTGCAACAC
D7 GCTGACATCCGGTTCGTCTACAC 487
GCTGGGTGGTAACTCTTTATTTCATTG
D17 GCTCCACGCAGAAAACCACACTTC 494
CAGGGCCAGCATTGCACAGTG
D26 GGAGCCGGAGCAGAAGCAAAG 157
GCGTTTGTGCCTGTCCTCACC
D45 GATGTGGACAGCAAGAGCATGC 323
GCAGGGCAGAAGGAATGGTGTAG
D51 CAGGGTCATTCATAGTAAAACTTTATTG 422
GAAGCCGTGATACAAATTGGTGAAC
D54 GCCATCGACGAATCTTATGATAAAC 205
CCAGTTTTATCCTTTTTTCTATCAGTC
D61 GATCATTCTTGGGTGTTTCTCGC 394
TGCCGGGTCTGTGTGGATAG
D64 GTCGATCAGGCAAAAGATC 246
GCAAAAAGTACAAGAATGTCTG
D76 CAGTGGCGAGTTCTTGGAGC 347
CAGCAATTTTGCAAGAGGCAG
D79 CAACGGCGGGCCAGGTCGTGG 109
CCAGCTTTGACCTTTATTCAAGAGACCAGATG
expressing cells. However, only the CCL1 transcript level was 
significantly increased in Jurkat T cells transiently transfected 
with  TIM3  expression  vector  as  well  as  in  human  primary 
CD4
＋ T  c e l l s  e x p r e s s i n g  a b u n d a n t l y  T I M - 3 .
MATERIALS AND METHODS
Cells and stimulation
The human Jurkat T cell line was cultured in RPMI1640 me-
dium (Gibco BRL, Paisley, Scotland) supplemented with 10% 
fetal bovine serum (FBS; Gibco BRL), 100 U/ml penicillin and 
100μg / m l  s t r e p t o m y c i n  ( G i b c o  B R L )  a t  3 7
oC  in  5%  CO2 
incubator. 
Construction of plasmids for expression of flag 
tagged TIM3
The human TIM-3 gene was cloned from peripheral blood 
mononuclear cells (PBMCs) stimulated with concanavalin A 
(ConA; 1μg/ml) for 2 days. Total RNA was subjected to re-
verse transcription-polymerase chain reaction (RT-PCR) us-
ing  the  human  TIM-3  specific  primers  [HTIM3F(KpnI)  5’- 
GGGGTACCGTTAAAACTGTGCCTAACAG-3’, HTIM3R(Hind III): 
5’-CCCAAGCTTCAAAAATAAGGTGGTTGG-3’] and then cloned 
into  a  pGEM-T  vector  (Promega,  Madison,  WI,  USA).  The 
TIM3  gene  amplified  with  specific  primers  [TIM3(Xho I): 
5’-CCGCTCGAGTACGAAGTGGAATACAGAGCG GAGG-3’ and 
TIM3(Xma I):  5’-TCCCCCCGGGCTATGGCATTGCAAAGCGACAAC-3’] 
was inserted into a pIRES2-EGFP vector (Clontech Laborato-
ries, Mountain View, CA, USA). The DNA fragment for leader 
and  flag  peptide  was  inserted  upstream  of  the  TIM-3  gene 
at  Nhe I  and  Xho I  sites.  The  nucleotide  sequences  were 
verified.
Establishment of stable cells expressing TIM-3 protein
The  pIRES2-EGFP-TIM3  vector  or  empty  vector  was  trans-
fected into Jurkat T cells using the Microporator (Digital Bio 
Technology,  Seoul,  Korea)  with  settings  of  1200  V,  pulse 
width  20  and  pulse  number  1.  Among  the  clones  resistant 
to neomycin, two independent clones (T5 and T7) that ex-
pressed TIM-3 on the surface and green fluorescence protein 
(GFP) in the cytoplasm were selected by flow cytometry. As 
controls, two independent clones expressing GFP alone were 
s e l e c t e d  ( G 2  a n d  G 6 ) .
Flow cytometry
For  TIM-3  detection,  cells  were  labeled  with  anti-human 
TIM-3-PE  (R&D  Systems,  Minneapolis,  MN,  USA)  and  ana-
lyzed using a FACSCanto II apparatus (Becton Dickinson, San 
Diego,  CA,  USA). 
Screening of differentially expressed genes using 
annealing control primer (ACP) system
Total RNAs of T5 and G2 were extracted using a RNA iso-
lation kit RNAiso (TaKaRa Bio, Shiga, Japan). cDNA synthesis 
and RT-PCR were performed following the procedures recom-
mended by the manufacturer using an annealing control pri-
mer system (Seegene, Seoul, Korea). PCR products were ana-
lyzed by agarose gel electrophoresis. Differentially amplified 
PCR  products  eluted  from  gel  were  cloned  into  a 
pCR2.1-TOPO  vector  (Invitrogen,  Carlsbad,  CA,  USA)  and 
then  sequenced.  The  identical  DNA  sequence  to  the  insert 
was  searched  using  BLASTN.
Semiquantitive RT-PCR and real-time RT-PCR
To validate the transcription level of the selected genes, sem-
iquantitive RT-PCR was performed using a specific primer set 
for  each  gene  (Table  I).  CCL1  transcription  level  was  as-TIM-3 Increases CCL1 Transcription
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Figure 1. TIM-3 expression in Jurkat T cell-derived stable cell clones.
Jurkat T cell-derived stable cell clones expressing TIM3 and/or GFP 
were established. The cells were labeled with PE-conjugated antibody
against TIM-3 and analyzed by flow cytometry.
sessed  by  real-time  RT-PCR  using  Sybr  Premix  Ex  Taq 
(TaKaRa,  Shiga,  Japan).  The  CCL1  primers  (Bioneer,  Dae-
jeon, Korea) were 5’-AATACCAGCTCCATCTGCTCCAA-3’ and 
5’-GAACCCATCCAACTGTGTCCAAG-3’.  CCL-1  transcription 
was normalized to glyceraldehyde 3-phosphate dehydrogen-
ase  (GAPDH)  transcription.
Isolation of primary CD4
＋ T cells and TIM-3
high T cells
Primary human CD4
＋ T cells were isolated from peripheral 
blood  mononuclear  cells  of  healthy  donors  using  magnetic 
beads  (Miltenyi  Biotec,  Bergisch  Gladbach,  Germany).  The 
cells were stimulated with antibodies against CD3 (1μg/ml) 
and CD28 (1μg/ml) for 7 days and then sorted into TIM-3 
high and TIM-3 low cells by fluorescence activated cell sort-
ing using a FACS Aria II cell sorter (BD, Franklin Lakes, NJ) 
after  labeling  with  allophycocyanin  (APC)-conjugated  an-
ti-TIM-3  antibody  (eBioscience, S a n  D i e g o ,  C A ) .  A l l  b l o o d  
samples  were  obtained  in  compliance  with  the  Ajou 
University  Institutional  Review  Board  protocol. 
Statistics
Student’s t-test was done with a p value＜0.05 being consid-
ered  significant.
RESULTS
Jurkat T cell clones over-expressing TIM-3
To identify the genes that were differentially expressed in T 
cells  by  TIM-3  expression,  we  established  cell  lines  over-
expressing TIM-3 by stably transfecting Jurkat T cells with an 
expression  vector  containing  TIM-3  gene  under  the  control 
of the cytomegalovirus promoter as well as a gene for GFP 
under the internal ribosome entry site. Cells expressing GFP 
were  sorted  twice  using  fluorescence  activated  cell  sorting 
(FACS) and then cloned. Compared to parental Jurkat T cells 
and GFP expressing clones (G2 and G6), TIM-3 expression 
in the T5 and T7 stable cell clones was clearly demonstrated 
(Fig.  1).
The differentially expressed gene candidates by 
TIM-3 expression
To screen for differentially expressed genes in TIM-3 express-
ing cells, RNA was isolated from Jurkat T cells, T5 cells stimu-
lated with phorbol 12-myristate 13-acetate (PMA) and A23187, 
and  then  RT-PCR  was  performed  using  an  ACP  system. 
Agarose gel electrophoresis selected 76 PCR products show-
ing  up-  or  down-regulated  expression  in  T5  compared  to 
Jurkat T cells for sequencing (Fig. 2). Sequence analysis of 
these genes showed that several PCR products with different 
ACP  sets  overlapped.  Eleven  differentially  expressed  gene 
candidates  were  identified  by  homology  search  using  the 
NCBI  dbEST  database  (Table  II).
Validation of difference in transcription of the 
candidate genes
To validate the candidate gene expression levels, semi-quanti-
tative RT-PCR was conducted using sequence specific primers 
and RNA isolated from Jurkat T cells, G2, G6, T5 and T7 (Fig. 
3).  The  transcription  of  TIMP-1,  IFITM1  and  CCL1,  re-
spectively,  was  increased  in  T 5  a n d  T 7  c e l l s ,  c o m p a r e d  t o  
control cells. CCL1 expression was induced in all cells when 
stimulated; the induction level was greater in T5 and T7 cells 
than  in  control  cells.  In  contrast,  the  transcription  of  PAR3 
was reduced in T5 and T7 cells compared to control cells. 
Next,  the  transcript  levels  of  these  genes  were  assessed  in TIM-3 Increases CCL1 Transcription
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Figure 2. Screening of differentially
expressed genes between Jurkat T 
cells and TIM-3 expressing cell 
clone. RNA was isolated from 
Jurkat T cells and T5, a stable clone
expressing TIM-3, stimulated with 
PMA (50 ng/ml) together with 
A23187 (0.5μM) for the indicated 
time, and then subjected to RT-PCR
using the ACP system. The PCR 
product was analyzed by agarose 
gel electrophoresis. The primer sets
used in PCR are indicated with 
ACP numbers and the differentially
expressed candidate gene PCR 
products are indicated with arrows.
Data are representative of the 
results from a total of 120 primer 
sets.
Table II. Homologous genes to the differentially expressed transcripts.
Clone 
Gene Gene bank accession number
identity
D6 Human enhancer of zeste homolog 2 (EZH2) gi 1575348 gb U61145.1
D7 Homo sapiens TIMP metallopeptidase inhibitor 1 (TIMP1) gi 73858576 ref NM_003254.2
D17 Homo sapiens interferon induced transmembrane protein 1 (9-27) (IFITM1) gi 150010588 ref NM_003641.3
D26 Homo sapiens arginine/serine-rich coiled-coil 2 (RSRC2) gi 301500650 ref NM_023012.5
D45 Homo sapiens chemokine (C-C motif) ligand 1 (CCL1) gi 4506832 ref NM_002981.1
D51 Homo sapiens HERPUD1 mRNA for stress protein Herp gi 9711684 gb AB034989.1
D54 Homo sapiens par-3 partitioning defective 3 homolog (C. elegans) (PARD3) gi 296278254 ref NM_019619.3
D61 Homo sapiens polycystic kidney and hepatic disease 1(autosomal recessive) (PKHD1) gi126131101 gb NM_138694.3
D64 Homo sapiens nuclear protein SDK3 gi 6563229 gb AF112222.1
D76 Homo sapiens Fas (TNFRSF6) associated factor 1 (FAF1) gi 19528653 ref NM_007051.2
D79 Homo sapiens Human cell cycle checkpoint control protein gi 1765955 gb U53174.1
cells transiently transfected with TIM3 expression vector (Fig. 
4). Only the CCL1 transcript level was significantly increased 
in  cells  transiently  transfected  with  TIM3  expression  vector 
compared  with  control  cells  (p＜0.05). TIM-3 Increases CCL1 Transcription
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Figure 3. CCL1 transcript levels increase in TIM-3 expressing stable
cells. RNA was isolated from Jurkat T cells, GFP expressing T cell 
clones (G2, G6) and TIM-3 expressing T cell clones (T5, T7) 
stimulated with PMA (50 ng/ml) together with A23187 (0.5μM) for 
4 h and then subjected to semi-quantitative RT-PCR using specific 
gene primers for the indicated genes. Data are representative of two
independent experiments. − unstimulated, ＋ stimulated with PMA 
(P) and ionophore (I; A23187).
Figure 4. CCL1 transcript level increases in transiently transfected 
Jurkat T cells with TIM-3 expression vector. Jurkat T cells were 
transfected with TIM-3 expression plasmid (TIM-3) or empty control 
plasmid (Con V). Twenty four hours later, the cells were stimulated 
with PMA (50 ng/ml) together with A23187 (0.5μM) for 4 h and then
subjected to semiquantitive RT-PCR using specific gene primers for 
the indicated genes. Data are mean±standard deviation of five 
independent experiments. P/I: PMA/A23187. *p<0.05.
Figure 5. CCL1 transcript levels increase in human primary CD4
＋ T
cells expressing high level of TIM-3. Primary human CD4
＋ T cells 
were stimulated with antibodies against CD3 (1μg/ml) and CD28 (1
μg/ml) for 7 days and then sorted into TIM-3 
high and TIM-3 
low T 
cells, respectively. The cells were restimulated with PMA (50 ng/ml) 
together with A23187 (0.5μM) for the indicated time and then 
subjected to real-time RT-PCR for CCL1. Data are mean±standard
deviation of triplicate. P/I: PMA/A23187. The increased transcription of CCL1 in human 
primary CD4
＋ T cells highly expressing TIM-3
Finally  we  examined  the  transcription  of  CCL1  in  primary 
CD4
＋ T cells highly expressing TIM-3 (Fig. 5). CD4
＋ T cells 
isolated from human subjects were stimulated for 7 days and 
then sorted into TIM-3 high cells and TIM-3 low cells. The 
cells were restimulated with PMA and A23187 and then CCL-1 
transcription was determined by real-time RT-PCR. Although 
the induction pattern of CCL-1 showed difference among sub-
jects, CCL-1 transcription was increased in TIM-3
high cells after 
stimulation  in  all  subjects  but  not  in  TIM-3  low  cells.
    Taken together, these data suggest that CCL1 transcription 
may be enhanced in CD4
＋ T cells highly expressing TIM-3.
DISCUSSION
Presently,  CCL1  was  identified  as  a  differentially  expressed 
gene in CD4
＋ T cells highly expressing TIM-3 compared to 
cells with TIM-3 low expression. CCL1 is produced by both 
Th1 and Th2 cells in response to T cell receptor triggering TIM-3 Increases CCL1 Transcription
Ka Jung Jun, et al.
208 IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 4 August 2011
(12). However, interleukin (IL)-12 and interferon (IFN)-alpha, 
cytokines that promote the differentiation of human Th1 cells 
selectively inhibit transcription and secretion of CCL1 by Th1 
cells  (12).  In  interferon-gamma  knockout  mice,  CCL1  ex-
pression is increased along with the elevation of the Th2-associ-
ated chemokines CCL11 and CCL17, and the Th17-associated 
chemokines CCL22 and CXCL2 (13). Given that TIM-3 is pref-
erentially expressed in fully differentiated Th1 cells, the in-
creased CCL1 transcription by CD4
＋ T cells highly expressing 
TIM-3  was  an  unexpected  result.
    CCL1, originally identified as a gene expressed in activated 
T  c e l l  l i n e s ,  i s  s e c r e t e d  b y  v a r i o u s  c e l l s  i n c l u d i n g  l y m p h o -
cytes,  Langerhans  cells,  monocytes,  mast  cells,  endothelial 
cells and epithelial cells (14,15). Its sole receptor, CC chemo-
k i n e  r e c e p t o r  ( C C R ) - 8 ,  i s  e x p r e s s e d  i n  p o l a r i z e d  T h 2  c e l l s ,  
IL-10 producing regulatory T cells and macrophages (16,17). 
Its chemotactic role for Th2 cells (16), and high serum levels 
in atopic dermatitis suggest that CCL1 plays a key role in the 
progression of Th2 type hypersensitivity (18,19). CCL1 togeth-
er  with  CCL22 participates  in the  migration  of regulatory T 
cells, leading to a reduced alloproliferative response (20,21). 
In mice, CCL1 interaction with CCR8 on macrophages leads 
t o  t h e  d e v e l o p m e n t  o f  p o s t o p e r a t i v e  a n d  p o s t i n f l a m m a t o r y  
peritoneal adhesions (22). Further studies are required to in-
vestigate CCL1 production by TIM-3-expressing CD4
＋ T cells 
in  normal  and  pathologic  immune  responses.
    Currently, TIM-3 is believed to play a negative role in cyto-
kine  production  by  Th1  and  Th17  cells  based  on  the  ob-
servations  that the  secretion  of  IFN-γ,  IL-2,  IL-17  and  IL-6 
by human CD4
＋ T cells is increased in the presence of an-
ti-TIM-3 antibody (23),  and that the  cytokine production of 
Th1 cells is enhanced by the injection of TIM-3-Ig into mice 
(2). It will be interesting to examine whether the expression 
o f  o t h e r  c h e m o k i n e s  i s  a f f e c t e d  b y  T I M 3  e x p r e s s i o n  a n d  
whether CCL1 expression is changed in the presence of an-
ti-TIM-3  antibody.
    In summary, TIM-3 expression in CD4
＋ T cells enhances 
transcription of CCL1, a chemotactic factor for CCR8
＋ polar-
i z e d  T h 2  c e l l s ,  r e g u l a t o r y  T  c e l l s  a n d  m a c r o p h a g e s .
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